Business Context and Reporting Period
Company: EyePoint, Inc. (EYPT)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended June 30, 2026
Business Overview: EyePoint is a clinical-stage biopharmaceutical company developing therapeutics for serious retinal diseases using its proprietary Durasert E technology. The lead product candidate, DURAVYU (vorolanib intravitreal insert), is in Phase 3 trials for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). The company operates as a single business segment.
Key Financial Metrics
| Metric (in thousands) | Q2 2026 | Q2 2025 | 6M 2026 | 6M 2025 |
|---|---|---|---|---|
| Total Revenues | $507 | $5,333 | $1,203 | $29,786 |
| Net Loss | $(94,470) | $(59,426) | $(179,302) | $(104,621) |
| Net Loss Per Share (Basic/Diluted) | $(1.09) | $(0.85) | $(2.08) | $(1.50) |
| Operating Expenses | $97,887 | $67,560 | $185,809 | $140,850 |
| R&D Expenses | $83,614 | $55,498 | $155,757 | $114,072 |
| Cash & Cash Equivalents | $110,458 | $71,143 | Balance Sheet Data | |
| Marketable Securities | $70,014 | $204,265 | Balance Sheet Data | |
| Total Liquidity (Cash + Investments) | $180,472 | $275,408 | Balance Sheet Data | |
| Accumulated Deficit | $(1,284,280) | $(977,637) | Balance Sheet Data |
Note: The filing does not provide explicit gross margin percentages due to negligible product sales and high R&D costs. Operating margins are negative.
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 90% in Q2 2026 ($0.5M) compared to Q2 2025 ($5.3M). This was driven by the cessation of deferred revenue recognition from the 2023 YUTIQ license agreement with ANI Pharmaceuticals and the termination of the SWK royalty purchase agreement in March 2025.
- Increased Operating Loss: Net loss increased 59% in Q2 2026 to $94.5M from $59.4M in the prior year quarter. The six-month net loss increased 71% to $179.3M.
- R&D Spend Surge: Research and development expenses increased 51% in Q2 2026 ($83.6M) and 37% for the six months ($155.8M). This increase is primarily attributable to ongoing Phase 3 clinical trials for DURAVYU (wet AMD and DME) and the scale-up of the Northbridge commercial manufacturing facility.
- Liquidity Position: While cash and cash equivalents increased to $110.5M from $71.1M year-over-year, total marketable securities decreased significantly from $204.3M to $70.0M as the company utilized investments to fund operations. Total liquidity stands at approximately $180.5M.
- Financing Activity: The company raised approximately $20.2M in gross proceeds during the six months ended June 30, 2026, through its At-The-Market (ATM) facility, selling 1.43 million shares.
Guidance, Outlook, and Risks
- Clinical Milestones:
- Wet AMD: Enrollment in pivotal Phase 3 trials (LUGANO and LUCIA) is complete. Initial data readout is expected in August 2026.
- DME: Enrollment in pivotal Phase 3 trials (COMO and CAPRI) was completed in July 2026. Initial data readout is expected in Q4 2027.
- Liquidity Outlook: Management believes current cash and investments ($180.5M) will fund operations into the fourth quarter of 2027, extending beyond the expected wet AMD topline data.
- Legal Settlement: On July 17, 2026, the company entered into a settlement agreement with the U.S. Department of Justice (DOJ) regarding a False Claims Act investigation into DEXYCU marketing practices. The settlement amount is approximately $4.7M plus interest, which was paid in full by July 31, 2026. The company also entered into a five-year Corporate Integrity Agreement with HHS.
- Legal Proceedings: EyePoint filed a complaint in March 2026 against Ocular Therapeutix, Inc., alleging defamation and commercial disparagement regarding DURAVYU clinical results. A preliminary injunction hearing is pending.
- Risk Factors: Key risks include the uncertainty of clinical trial outcomes, the ability to obtain FDA approval for DURAVYU, the need for additional capital raises (which may be dilutive), and the impact of ongoing litigation.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $180.5M liquidity position to fund operations through Q4 2027, considering potential delays in clinical trials or regulatory approvals.
- Revenue Sustainability: Assess the impact of the near-total loss of royalty and license revenue streams (ANI and SWK agreements) on future cash flow projections.
- DOJ Settlement Impact: Confirm the full payment of the ~$4.7M DOJ settlement and review the compliance requirements of the new Corporate Integrity Agreement.
- Clinical Data Readouts: Monitor the August 2026 data readout for the wet AMD Phase 3 trials as a critical value inflection point.
- Equity Dilution: Track future ATM facility sales and potential new capital raises required to bridge the gap between current cash and commercialization costs.